Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

LISBON, Portugal — For most people with systemic sclerosis, adverse effects on the lungs, heart, skin, and other systems develop early and quickly, a large-scale, longitudinal study has confirmed for ...

Please provide your email address to receive an email when new articles are posted on . Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...